Divi’s Labs Stock Price: The shares of Pharma Company Divise Laboratories Limited may show up to 26 percent further. Brokerage firm City has given a target price of Rs 7750 per share, retaining the ‘bye’ rating for this stock. This is 26 percent higher than the closing price of the share on BSE on Friday, August 22. Brokerage says that recent weakness in the stock is a good chance of shopping. According to the city, the valuation of the divis laboratories is appropriate due to favorable conditions in the pharma sector and the orders present with the company.
The concerns of Antresto being generic in the US may gradually decrease. The company continues to supply API without any change. Antresto is the blockbuster drug of Novartis to treat cardiac arrest. It generates about $ 6 billion sales for the company. Divi’s Laboratories’ active pharmaceutical ingredients (Novartis are expected to be a prominent supplier of Apto for Entresto.
Innovator Custom synthesis (CS) of Divise Laboratories is expected to be the biggest product in Antresto API in the portfolio. It is estimated that it will contribute up to 40% to the company’s custom synthesis revenue and contribute about 20% to the consolidated revenue.
Shares strong 25 percent in a year
Divis laboratories The stock closed at Rs 6150.70 at BSE on Friday, August 22. The company’s market cap is Rs 1.63 lakh crore. The stock has climbed 25 percent in a year. The company had 51.89 percent stake in the company till the end of June 2025. 11 out of 30 analysts covering the share of Divise Laboratories have given it “by” rating, 6 “hold” and 13 have given “sale” ratings. The face value of the stock is Rs 2. The share of 52 weeks high levels on BSE is Rs 7077.70, which was created on 8 July 2025. The 52 -week low of Rs 4831 was seen on 23 August 2024.
Profit 557 crores in June quarter
The Revenue of Divise Laboratories on the April 2025 quarter was Rs 2357 crore on the standalone basis. Meanwhile, the net profit was Rs 557 crore and Earnings was Rs 20.95 crore per share. In FY 2025, the company’s standalone revenue was recorded at Rs 9198 crore, net profit of Rs 2209 crore and earnings per share was Rs 83.20 crore.
Disclaimer: Advice or idea experts/brokerage firms given on Moneycontrol.com have their own personal views. The website or management is not responsible for this. Moneycontrol advises to users that always seek the advice of certified experts before taking any investment decision.